We develop innovative stem cell-based biopharmaceuticals for use in companion animals. The share of biopharmaceuticals in the entire pharmaceutical market is forecast to increase by up to 28% by 2020. This translates to USD 390 billion spent on biological treatments alone.
We develop innovative therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. We target common diseases in companion animals which result in high demand for new, more effective medicinal products.
The Bioceltix business model follows global quality standards for advanced therapy medicinal products (ATMPs) for humans. All biopharmaceuticals developed by Bioceltix will be subject to independent clinical trials to verify their quality and safety. We possess cutting-edge research and production facilities, cooperate with ambitious scientists, and operate based on a clearly defined commercialisation route. Our goal is to market new, effective solutions in the field of veterinary medicine.
Spending on therapies for companion animals grows year by year. The American Pet Products Association estimates that in the United States alone, the spending reached about USD 69 billion in the years 2016-2017. Almost 15 billion USD (about 20%) was spent on pharmaceutical therapies.
the number of veterinarians working in private practice in the EU and the USA
30 billion USD
spending on treatment for companion animals in the USA and the EU in 2022
increase in the share of biopharmaceuticals in the entire pharmaceutical market by 2020
At Bioceltix, we harness the therapeutic potential of MSCs to develop innovative biopharmaceuticals for companion animals focusing on diseases with high demand for new, effective therapies. The pharmaceuticals, intended for use in animals and based on the immunomodulatory mechanism of action of MSCs, will be an excellent alternative to symptomatic pharmacotherapy focused mainly on alleviating pain and inflammation.
1Mesenchymal stem cells (MSCs) used as an active pharmaceutical ingredient are a viable alternative to steroidal and non-steroidal anti-inflammatory drugs.
2MSCs induce natural pathways of intracellular signal transduction, having a strong anti-inflammatory, analgesic and pro-regenerative effect.
3MSCs are a long acting API whose therapeutic effect is based on stimulating the natural processes of the body – they cause no adverse reactions
4They can actively facilitate the regeneration of the damaged tissue
Our technology for developing and manufacturing MSC-based medicinal products for veterinary use utilises the therapeutic potential of allogeneic stem cells (one donor – many recipients).
This means that:
Stem cells are one of the hottest issues in contemporary medicine. Their enormous and still not fully discovered potential inspires us to perform research studies on new drugs for the veterinary market. Our plan for the coming years includes pushing Bioceltix products into the next, key stages of development:
|Target group||Product||Therapeutic area||Stage|
|Dog||BCX-CM-J||Degenerative joint lesions (Osteoarthritis)||Pre-clinical trials|
|Dog||BCX-CM-S||Autoimmune and inflammatory diseases in dogs||Pre-clinical trials|
|Horse||BCX-EM||Tendon damage||Pre-clinical trials|
|Target group||Product under development||Intended use||Stage|
|Dog||Medicine for atopic dermatitis||Atopy in dogs||R&D|
|Dog||Tests and targeted therapy for lymphoma and leukaemia in dogs||Diagnosis and anti-cancer treatment in dogs||R&D|
|Dog/Horse||WJMSC – mesenchymal stem cells isolated from the foetal tissue of dogs and horses||Diseases and injuries of the muscoskeletal system, organ failure, and neurological diseases in dogs and horses||R&D|
|MSC-based biopharmaceuticals||Stem cell lyophilisation||A technology for obtaining a lyophilisate from stem cells to facilitate their revival directly before their administration||R&D|
The business model of Bioceltix is based on: